Assessment of child growth is problematic: growth is nonlinear in the long-term, and unpredictable in the short-term; growth is subject to a number of environmental as well as genetic influences; and growth is difficult to measure reliably. The potential for growth delay as an effect of asthma is established, although it has proved difficult to quantify how great an impact this has on height, growth velocity, or final attained height. In the treatment of asthmatic children, there remain uncertainties as to the effect of inhaled corticosteroids on growth, given the great number of factors affecting growth. In this paper we present recommendations for the design and analysis of trials to assess the effect of regular treatment with inhaled corticosteroids on growth in asthmatic children. Design recommendations are articulated for study duration, entry criteria, other factors that may affect growth, measuring height, measuring growth, study objectives, and considerations relating to confounding between treatment allocation and the effect of the disease on growth. Special attention is given to analyses that address both the intra-subject correlation arising from multiple measurements in longitudinal studies of growth and the potential bias in treatment comparisons due to dropouts, especially those due to treatment failure.
KamadaAKSzeflerSJGlucocorticoids and growth in asthmatic children. Pediatr Allergy Immunol.1995;6:145–154.
2.
AllenDBGrowth suppression by glucocorticoid therapy. Endocrinol Metab Clin North Am.1996;25: 699–717.
3.
AllenDBBronskyEALaForceCFNathanRATinkelmanDGVandewalkerMLKonig P, and the Fluticasone Propionate Asthma Study Group. Growth in asthmatic children treated with fluticasone propionate. J Pediatr.1998;132:472–477.
4.
MielckAReitmeirPWjstM.Severity of childhood asthma by socio-economic status. Int J Epidemiol.1996;25(2):388–393.
5.
PriceJFRussellGHindmarshPCWeilerPHeafDPWilliamsJ.Growth during one year of treatment with fluticasone propionate or sodium cromoglycate in children with asthma. Pediatr Pulmonal.1997;24:178–186.
6.
BlodgettFMBurginLIezzoniDGribetzDTalbotNBEffect of prolonged cortisone treatment of statural growth, skeletal maturation, and metabolic status of children. N Engl J Med.1956;254:636.
7.
van MetreTEPinkertonHLGrowth suppression in asthmatic children receiving prolonged therapy with prednisone and methylprenisolone. J Allergy.1959;30:103–113.
8.
Guidelines for the Diagnosis and Management of Asthma: Expert Report Panel 2.Bethesda, MD: National Institutes of Health; 1997. Publication 97–4051.
9.
AgercroftLPedersenS.Effects of longterm treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med.1994;88:373–381.
10.
NinanTKRussellG.Asthma, inhaled corticosteroid treatment, and growth. Arch Dis Child.1992;67: 703–705.
11.
LemanskeRFAllenDBChoosing a long-term controller medication in childhood asthma, the proverbial two-edged sword. Am J Respir Crit Care Med.1997;156:685–687.
12.
VossLDBaileyBJRDiurnal variation in stature: is stretching the answer?Arch Dis Child.1997;77: 319–322.
13.
TannerJMDaviesPSWClinical longitudinal standards for height and height velocity for North American children. J Pediatr.1985;107:317–329.
14.
VossLDBaileyBJREquipping the community to measure children's height: the reliability of portable instruments. Arch Dis Child.1994;70:469–471.
15.
KennisT.Inhaled corticosteroids—the FDA takes another look. Ann Allergy Asthma Immunol.1998;81:406–410.
16.
ElashoffB.The draft guidance for the design of studies to assess the effects of inhaled and intranasal corticosteroids on growth: describing a regulatory perspective. FDA/Industry Workshop—Statistical Issues for the New Millennium. Sept 30-Oct 1, 1999, Arlington, VA.
17.
LipworthBJSystemic adverse effects of inhaled corticosteroid therapy. Arch Intern Med.1999;159:941–955.
18.
LittIFFaughanVCIIIGrowth and development during adolescence. In: BerhmanREVaughanVCIII, editors. Nelson Textbook of Pediatrics.13th ed.Philadelphia, PA: WB Saunders; 1987, 20–124.
19.
MurrayABFraserBMHardwickDFPirieGEChronic asthma and growth failure in children. Lancet.1976; July 4:197–198.
20.
EskenaziBBergmannJJPassive and active maternal smoking during pregnancy, as measured by serum cotinine, and postnatal smoke exposure. I. Effects on physical growth at age 5 years. J Epidemiol.1995;142(Suppl 9):S10–81.
21.
KrickJ.Using the Z Score as a descriptor of discrete changes in growth. Nutritional Sup Ser.1966;6:15–17.
22.
RaoRGregsonRKJonesACMilesEACampbellMJWarnerJOSystemic effects of inhaled corticosteroids on growth and bone turnover in childhood asthma: a comparison of fluticasone with beclomethasone. Eur Respir J.1999;13:87–94.
23.
ClarkPAOldsBMortonRSheikhSHowellLEddyMShoemakerLLooneySAbellTEidN.Reduction in growth velocity in children and adolescents with asthma treated with inhaled fluticasone. Pediatr Res.1999;45(4):2068.
24.
de BenedictisFMMedleyHVWilliamsL.Long-term study to compare the safety and efficacy of fluticasone propionate (FP) with beclomethasone dipropionate (BDP) in asthmatic children. Eur Respir J.1999;12(Suppl 28):142S.
25.
FergusonACSpierSManjraAVersteeghFGAMarkSZhangP.Efficacy and safety of high-dose inhaled steroids in children with asthma: A comparison of fluticasone propionate with budesonide. J Pediatr.1999;134:422–427.
26.
HermanussenMGeiger-BenoitKBurmeisterJSippellWGPeriodical changes of short term growth velocity ('mini growth spurts') in human growth. Ann Hum Biol.1988;15:103–109.
27.
WelchMJInhaled corticosteroids and growth in children. Pediatr Ann.1998;27:752–758.
28.
SaariSMVidgrenMTKoskinenMOTurjanmaaVMHWaldrepJCNieminenMMRegional lung deposition and clearance of 99mTC-labeled beclomethasone-DLPC liposomes in mild and severe asthma. Chest.1998;113:1573–1579.
29.
LittleRJARubinDBStatistical Analysis of Missing Data.New York, NY: Wiley; 1987.
30.
GoldsteinH.Efficient statistical modeling of longitudinal data. Ann Hum Biol.1986;13:129–141.
31.
GhoshMGrizzleJESenPKNonparametric methods in longitudinal studies. J Am Stat Assoc.1973;68(341):29–36.
32.
BoxGEPJenkinsGMTime Series Analysis: Forecasting and Control.2nd ed.San Francisco; Holden-Day: 1976.
33.
SAS Institute Inc., SAS/STAT Software: Changes and enhancements through Release 6.12.Cary, NC: SAS Institute Inc.; 1997.
34.
RubinDBMultiple imputation in health-care databases; an overview and some applications. Stat Med.1991;10:585–598.
35.
RubinDBMultiple Imputation for Nonresponse in Surveys.New York, NY: Wiley; 1987.
36.
LittleRJAModeling the dropout mechanism in repeated measures studies. J Am Stat Assoc.1995;90(431):1112–1121.
37.
RussellG.Childhood asthma and growth—a review of the literature. Respir Med.1994;88(Supp. A):31–37.
